FGFelix Götzinger

Felix Götzinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Felix Götzinger has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Felix Mahfoud

    University Hospital Basel

    10 shared publications
  • Felix Mahfoud

    Department of Cardiology and Cardiovascular Research Institute Basel, University Heart Center Basel, University Hospital Basel, Basel, Switzerland

    9 shared publications
  • Lucas Lauder

    Department of Cardiology and Cardiovascular Research Institute Basel, University Heart Center Basel, University Hospital Basel, Basel, Switzerland

    8 shared publications
  • Michael Böhm

    Department of Internal Medicine III – Cardiology, Angiology and Intensive Care Medicine, University Hospital Homburg, Homburg, Germany

    8 shared publications
  • Michael Kunz

    Department of Cardiology and Cardiovascular Research Institute Basel, University Heart Center Basel, University Hospital Basel, Basel, Switzerland

    8 shared publications
  • Lucas Lauder

    University Hospital Basel, University of Basel

    6 shared publications

Latest Publications

  • Open Access

    Aspirated thrombus weight and volume are not associated with improvements in hemodynamics after large-bore mechanical thrombectomy in pulmonary embolism

    by Felix Götzinger, Lucas Lauder, Patricia Perez Navarro, Michael Kunz, Mathias Wagner, Mert Tokcan, Jasper Boeddinghaus, Gregor Leibundgut, Michael Böhm, Andreas Link, et al.

    Background: Large-bore mechanical thrombectomy (LBMT) is a catheter-directed therapy for acute pulmonary embolism (PE). The relationship between aspirated thrombus weight and volume with outcomes remains unclear. Aims: The aim was to evaluate the impact of aspirated thrombus weight and volume on outcomes after LBMT. Methods: This prospective, open-label, single-arm, single-center registry study included 48 patients undergoing LBMT using the FlowTriever system (Inari Medical/Stryker, Irvine, CA, USA). Thrombus weight and volume were quantified, and clot composition assessed. Associations between thrombus characteristics and clinical, invasive hemodynamics, echocardiographic parameters, and biomarkers were evaluated immediately after the procedure, at hospital discharge, and at 3-month follow-up. Results: Thrombus material was available in 48 patients (31% women), of which 41 presented with intermediate-risk and 7 with high-risk PE. LBMT resulted in significant reductions in systolic pulmonary artery pressures (sPAP) intraprocedurally (− 12.8 ± 8.3 mmHg, p < 0.001), with a further invasively measured decrease through 3 months (− 9.6 ± 10.6 mmHg, p < 0.001). From baseline to discharge, right ventricular coupling improved (+ 0.24, p < 0.001) and right ventricle (RV)/left ventricle (LV) ratio decreased (− 0.23, p < 0.001). NT-proBNP and high-sensitivity cardiac troponin T declined significantly. Neither thrombus weight nor volume correlated with acute changes in sPAP ( ρ volume = 0.06; ρ weight = 0.10), RV-uncoupling ( ρ volume = 0.47; ρ weight = 0.46), and RV/LV ratio ( ρ volume = − 0.02; ρ weight = − 0.005) ( p for all > 0.05), nor with outcomes at 3 months. Conclusions: Aspirated thrombus weight and volume were not associated with improvements after LBMT, suggesting that, beyond mechanical obstruction, additional mechanisms potentially including paracrine and endocrine effects of thrombus material may contribute to acute and chronic PE-related cardiopulmonary dysfunction. Graphical Abbreviations: PE – pulmonary embolism, LBMT – large bore mechanical thrombectomy, PVR - pulmonary vascular resistance, RV – right ventricular, TTE – transthoracic echocardiography, sPAP – systolic pulmonary artery pressure, IQR – interquartile range, BH – Benjamin Hochberg. Acknowledgment: Images partly created with AI

  • Reply to Letter regarding the article ‘Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation’

    by Felix Götzinger, Thorald Stolte, Thomas Nestelberger, Felix Mahfoud

    Felix Götzinger, Thorald Stolte, Thomas Nestelberger, Felix Mahfoud; Reply to Letter regarding the article 'Prevalence and influence of cardiovascular kidn


  • Open Access

    Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation

    by Felix Götzinger, Thorald Stolte, Jakob J Reichl, Anke von Peter, Michael Kunz, Mirjam G Wild, Max Wagener, Christoph Kaiser, Christian Mueller, Dirk Westermann, et al.

    Aim: The cardiovascular kidney metabolic syndrome (CKM) is a multisystem disorder increasingly recognized for its association with adverse outcomes. The incidence and prognostic relevance of CKM in patients undergoing transcatheter aortic valve implantation (TAVI) has not been investigated. Methods: A double-centre, retrospective analysis of patients undergoing TAVI from 2011 to 2024 was performed. CKM syndrome was diagnosed and quantified using a simplified definition based on the presence of atherosclerotic cardiovascular diseases, chronic kidney disease, and diabetes mellitus. The prevalence of CKM and its association with procedural success, bleeding events, permanent pacemaker implantation and 1-year mortality was evaluated. Results: Among 5834 TAVI patients, 5280 (90%) fulfilled criteria for CKM. The overall prevalence remained stable. Procedural success was highest in patients with no CKM conditions, followed by patients with one and two CKM conditions. Patients with three CKM conditions had the lower procedural success. Patients with two and three CKM conditions had higher probability of death within 1 year as compared to patients with no CKM conditions [hazard ratio (HR) for two CKM conditions 1.40, P = .030, HR for three CKM conditions 1.88, P < .001]. Patients with three CKM conditions had higher rates of permanent pacemaker implantation (OR 1.45, P = .02) but not of major bleeding (HR 1.33, P = .336). After adjustment for baseline differences in comorbidities and patient characteristics, 3/3 CKM conditions remained associated with increased all-cause mortality at 1, 2, and 5 years. Conclusion: CKM is highly prevalent in patients undergoing TAVI. Higher CKM condition burden was associated with adverse outcomes.


  • Unveiling Cardiac Complications: A Case of Amisulpride Overdose Leading to Bradycardia, QT-Prolongation, and Torsade de Pointes Tachycardia

    by Michael Kunz, Lea Wagmann, Michael Schuster, Felix Götzinger, Andreas Link, Felix Mahfoud

    Suicide attempts involving self-poisoning with benzodiazepines, antipsychotic drugs, or antidepressants are prevalent in emergency departments and intensive care units. Managing these patients is often complex and relies predominantly on local expertise and experience. Treatment options for overdose of orally ingested substances include gastroscopy with gastric lavage and activated charcoal therapy. However, there are limited data regarding the effectiveness of delayed treatment initiation and associated clinical benefits. Overdose with antipsychotic drugs, such as amisulpride, can lead to severe cardiac side effects, including bradycardia, QT prolongation, and subsequent torsade de point tachycardia. This report describes a 65-year-old woman who ingested of 40g amisulpride with suicidal intent. The patient presented with bradycardia necessitating temporary pacing and QT prolongation, which resulted in torsade de point tachycardia. Due to the severe cardiac, hemodynamic, and central nervous system complications of the intoxication, the authors opted for gastroscopy with gastric lavage and activated charcoal therapy, despite the intake taking place >7 hours ago. Amisulpride plasma concentrations were measured using liquid chromatography coupled with high-resolution mass spectrometry at various time points, including before and after gastroscopy. In addition, a qualitative measurement of amisulpride in stomach contents was performed. Drawing insights from this case, the authors explored optimal approaches for managing cardiac side effects and assessed the value of gastric lavage and activated charcoal therapy in contemporary intensive care medicine. Why should physicians and toxicologists be aware of this issue? (1) To detect and treat possible cardiac side effects, such as torsade de point tachycardia, and (2) To understand the role of gastric lavage and activated charcoal therapy in patients with poisoning.


  • Open Access

    Advanced Management of Patients Undergoing Transcatheter Treatment for Pulmonary Embolism: Evidence-Based Strategies for Optimized Patient Care

    by Francesco Costa, Alfonso Jurado-Román, Gabriele Carciotto, Victor Becerra-Munoz, Daniel Tébar Márquez, Felix Götzinger, Enrico Cerrato, Shantum Misra, Marco Spissu, Marco Pavani, et al.

    Pulmonary embolism (PE) is a life-threatening medical condition caused by the thrombotic occlusion of one or more branches of the lung vasculature, which represents the third most common cause of cardiovascular mortality after myocardial infarction and stroke. PE treatment requires a tailored approach based on accurate risk stratification and personalized treatment decision-making. Anticoagulation is the cornerstone of PE management, yet patients at higher clinical risk may require more rapid reperfusion therapies. In recent years, transcatheter treatment has emerged as a valuable option for patients with intermediate–high or high-risk PE who have contraindications to systemic thrombolysis. Recent advancements in catheter-directed therapies, such as catheter-directed thrombolysis (CDT) and catheter-directed mechanical thrombectomy (CDMT), provide minimally invasive options for swift symptom relief and hemodynamic stabilization. This review aims to provide a practical approach for optimal patient selection and management for PE percutaneous therapies, supported by a thorough evaluation of the current evidence base supporting these procedures. A focus on post-procedural management, the prevention of recurrence, and monitoring for long-term complications such as chronic pulmonary hypertension and post-PE syndrome is also specifically tackled.


  • New ways of mitigating aldosterone in cardiorenal disease

    by Felix Götzinger, Michael Kunz, Lucas Lauder, Michael Böhm, Felix Mahfoud

    Steroidal mineralocorticoid receptor antagonists (MRAs) bind to the mineralocorticoid receptor and antagonize the effects of aldosterone, which contributes to the development and progression of cardio- and renovascular diseases. Guidelines recommend steroidal MRAs in patients with heart failure with reduced or mildly reduced ejection fraction, as they reduce morbidity and mortality. In heart failure with preserved ejection fraction, MRAs have not convincingly shown to improve prognosis. Steroidal MRAs delay the progression of chronic kidney disease, reduce proteinuria and lower blood pressure in resistant hypertension but can induce hyperkalaemia. Due to their limited selectivity to the mineralocorticoid receptor, steroidal MRAs can cause significant adverse effects, i.e. libido loss, erectile dysfunction, gynaecomastia, and amenorrhoea, leading to low rates of persistance. Against this background, new avenues for developing non-steroidal, selective (ns)MRAs and aldosterone-synthase inhibitors have been taken. Finerenone has been shown to delay the progression of diabetic nephropathy and lower the incidence of heart failure hospitalizations in patients with chronic kidney disease and diabetes compared with placebo. Finerenone has therefore been recommended by the 2023 European Society of Cardiology Guidelines for the management of diabetes in patients with type 2 diabetes and chronic kidney disease. Further randomized controlled trials assessing the safety and effectiveness of finerenone in patients with heart failure are currently ongoing. Esaxerenone provides antihypertensive effects and has been approved for the treatment of hypertension in Japan. Baxdrostat and lorundostat, novel selective aldosterone-synthase inhibitors, are currently under investigation. In phase II trials, baxdrostat and lorundostat were safe and effective in lowering blood pressure in resistant hypertension. In this review, we summarize and critically discuss the evidence for new drugs mitigating aldosterone in heart failure, hypertension, and chronic kidney disease.


  • Use of fixed-dose combinations for cardiovascular indications from 2018 to 2023: a nationwide population-based study

    by Felix Götzinger, Marita Kieble, Andrea Espinosa Daudí, Michael Kunz, Lucas Lauder, Michael Böhm, Ulrich Laufs, Felix Mahfoud, Martin Schulz

    Aims: Clinical guidelines support the use of fixed-dose combinations (FDC) for prevention of cardiovascular disease. Implementation of FDC into clinical care remains challenging, and current population-based data are scarce. Methods and results: Claims data on dispensed drugs in an outpatient care setting of approximately 87% of the German population were analysed regarding the use of FDC according to time, age of the insured persons, and active ingredients. The overarching trend for all FDC revealed a decrease from 77.3 defined daily doses per 1000 statutory health-insured (SHI) persons per day (DID) in the second half-year of 2018 (2018HY02) to 60.8 DID in the first half-year of 2023 (2023HY01) (Spearman ρ = -0.988; P < 0.001). The total DID for all antihypertensives (AHT) increased from 590.6 in 2018HY02 to 624.8 in 2023HY01 (ρ = 0.855; P = 0.002), but the DID for fixed-dose AHT (AHT-FDC) declined from 74.1 in 2018HY02 to 55.0 in 2023HY01 (ρ = -0.988; P < 0.001). Conversely, the use of all lipid-lowering agents (LLA) and LLA-FDC continuously increased: The total DID of all LLA rose from 92.5 in 2018HY02 to 134.4 in 2023HY01 (ρ = 1.000; P = 0.000), and for LLA-FDC from 3.1 in 2018HY02 to 5.5 DID in 2023HY01 (ρ = 0.915; P < 0.001). AHT-FDC and LLA-FDC were less frequently dispensed to patients at least 80 years than to patients less than 80 years. Dispensing of multiple purpose FDC increased from 2018HY02 to 2023HY01 from 0.11 DID to 0.26 DID (ρ = 1.000; P = 0.000) but remained negligible. Conclusion: Use of AHT-FDC in Germany is declining. In contrast, FDC containing LLA are increasingly prescribed. Dispensing of multiple purpose FDC is very low. Strategies are needed to facilitate the use of FDC as recommended by current guidelines.


  • Open Access

    Ultrasound‐assisted endovascular thrombolysis versus large‐bore thrombectomy in acute intermediate‐high risk pulmonary embolism: The propensity‐matched EKNARI cohort study

    by Hani Al‐Terki, Lucas Lauder, Andreas Mügge, Felix Götzinger, Abdelrahman Elhakim, Felix Mahfoud

    Background: Ultrasound‐assisted thrombolysis (USAT) and large‐bore‐thrombectomy (LBT) are under investigation for the treatment of intermediate‐high and high‐risk pulmonary embolisms (PE). Comparative studies investigating both devices are scarce.Aims: This study aimed to compare the safety and efficacy of the two most frequently used devices for treatment of acute PE.Methods: This multicenter, retrospective study included 125 patients undergoing LBT or USAT for intermediate‐ or high‐risk PE between 2019 and 2023. Nearest neighbor propensity matching with logistic regression was used to achieve balance on potential confounders. The primary outcome was the change in the right to left ventricular (RV/LV) ratio between baseline and 24 h.Results: A total of 125 patients were included. After propensity score matching, 95 patients remained in the sample, of which 69 (73%) underwent USAT and 26 (27%) LBT. The RV/LV ratio decrease between baseline and 24 h was greater in the LBT than in the USAT group (adjusted between‐group difference: −0.10, 95% CI: −0.16 to −0.04; p = 0.001). Both procedures were safe and adverse events occurred rarely (10% following USAT vs. 4% following LBT; p = 0.439).Conclusion: In acute intermediate‐high and high‐risk PE, both LBT and USAT were feasible and safe. The reduction in RV/LV ratio was greater following LBT than USAT. Further randomized controlled trials are needed to confirm these findings.


  • Open Access

    Hidden sodium in effervescent-tablet dietary supplements and over-the-counter drugs: a comparative cross-sectional study

    by Michael Kunz, Felix Götzinger, Cathy M Jacobs, Lucas Lauder, Christian Ukena, Markus R Meyer, Ulrich Laufs, Martin Schulz, Michael Böhm, Felix Mahfoud

    Objective Dietary sodium intake represents a risk factor for cardiovascular disease and mortality. The study sought to analyse the sodium content of effervescent dietary supplements and drugs in Germany and the USA. Design Comparative cross-sectional study. Setting and methods The sodium content of 39 dietary supplement effervescent tablets available in Germany was measured in May and June 2022 using optical emission spectrometry with inductively coupled argon plasma. The sodium content of 33 common pharmacy-only effervescent tablets (over-the-counter (OTC) drugs) in Germany was obtained from the summary of product characteristics. We compared the sodium content of the measured German dietary supplement effervescent tablets to that of 51 dietary supplement effervescent tablets available in the USA (data: National Institutes of Health’s Dietary Supplement Label Database). Results The measured sodium content in the German dietary supplements was 283.9±122.6 mg sodium/tablet, equivalent to 14±6% of the maximum recommended daily sodium intake (MRDSI). Vitamin products had the highest (378.3±112.8 mg, 19±6% of MRDSI), and calcium products had the lowest mean sodium content (170.4±113.2 mg, 9±6% of MRDSI). Vitamin products contained significantly more sodium than magnesium (378.3 mg vs 232.7 mg; p=0.004), calcium (378.3 mg vs 170.4 mg; p=0.006) and mineral products (378.3 mg vs 191.6 mg; p=0.048). The sodium content measured in products available in Germany was higher when compared with the declared sodium content on the label of the products sold in the USA (283.9 mg vs 190.0 mg; pConclusion Effervescent tablets of nutritional supplements and OTC drugs contain high amounts of sodium, which often is not disclosed.